Logo En IconLogo Mark IconIcelandic Intellectual Property Office

EP2909201

ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR

  • Status:
    EP einkaleyfi: Þýðing ekki lögð inn
  • EP appl. date:
    21.10.2013
  • EP published:
    22.2.2017
  • EP application number:
    13785389.1
  • Max expiry date:
    20.10.2033
  • Title:
    ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR

Timeline

Today
21.10.2013EP application
22.2.2017EP Publication

Owner

  • Name:
    AbbVie Deutschland GmbH & Co. KG
  • Address:
    Mainzer Strasse 81, 65189, Wiesbaden, DE
  • Name:
    AbbVie Inc.
  • Address:
    1 North Waukegan Road, 60064, North Chicago, IL, US

Inventor

  • Name:
    HAUPT, Andreas
  • Address:
    Ludwigshafen, DE
  • Name:
    DINGES, Jürgen
  • Address:
    North Chicago, Illinois, US
  • Name:
    UNGER, Liliane
  • Address:
    Ludwigshafen, DE
  • Name:
    WICKE, Karsten
  • Address:
    Ludwigshafen, DE
  • Name:
    VAN WATERSCHOOT, Robert
  • Address:
    Riehen, CH
  • Name:
    MITTELSTADT, Scott
  • Address:
    North Chicago, Illinois, US
  • Name:
    DRESCHER, Karla
  • Address:
    Ludwigshafen, DE
  • Name:
    RELO, Ana
  • Address:
    Ludwigshafen, DE

Priority

  • Number:
    201261716824 P
  • Date:
    22.10.2012
  • Country:
    US
  • Number:
    201361777114 P
  • Date:
    12.3.2013
  • Country:
    US

Classification

  • Categories:
    C07D 405/14, C07D 403/04, C07D 405/04, C07D 239/42, A61K 31/506, A61P 25/00

Upload documents